Cibus, Inc.

Cibus, Inc. is an agricultural biotechnology company that leverages proprietary gene editing technologies, specifically its Rapid Trait Development System (RTDS®) and Trait Machine™ process, to develop plant traits for major agricultural crops. The company's core business model involves licensing these traits to seed companies for a royalty, a long-standing practice in the agricultural industry. Cibus focuses on productivity traits that address challenges such as weeds, pests, diseases, and environmental factors like heat and drought, aiming to improve crop yields, profitability, and sustainability. The company also has a secondary program focused on sustainable ingredients, including lauric oils and biofragrance products, which is partially partner-funded ¹. Cibus's gene-edited traits are designed to be non-transgenic, distinguishing them from genetically modified organism (GMO) technologies and potentially offering regulatory and adoption advantages in various markets.

The company's primary near-term revenue generation priority is its Rice herbicide tolerance (HT) traits, HT1 and HT3, which management estimates have potential annual addressable royalties exceeding $200.0 million upon full commercialization in initial target markets of Latin America and the United States ². Beyond Rice, Cibus maintains rights to a broader productivity trait portfolio, including Canola (Pod Shatter Reduction, Weed Management (HT), Sclerotinia Resistance) and Soybean (Weed Management (HT), Sclerotinia Resistance), which it plans to pursue opportunistically through partner-funded projects ³. The sustainable ingredients program, including biofragrance products, is partially funded by a consumer-packaged goods partner, Procter & Gamble (P&G), and aims to provide bio-based natural alternatives to expensive natural extractions or synthetic fragrance products ⁴.

For the fiscal year ended December 31, 2025, Cibus reported total revenue of $3.6 million ⁵, a decrease of $0.6 million or 15% from $4.262 million in 2024 ⁶. The company incurred a net loss of $132.2 million ⁷ for 2025, an improvement from a net loss of $282.713 million in 2024 ⁸. Basic and diluted net loss per share of Class A common stock was $(2.78) ⁹ in 2025, compared to $(10.83) ¹⁰ in 2024. Research and development (R&D) expenses decreased by $6.2 million or 12% to $44.2 million ¹¹ in 2025 from $50.429 million in 2024 ¹², primarily due to cost reduction initiatives. Selling, general, and administrative (SG&A) expenses also decreased by $3.9 million or 13% to $26.9 million ¹³ in 2025 from $30.797 million in 2024 ¹⁴, partially offset by a $2.6 million litigation liability ¹⁵.

Goodwill impairment in 2025 was $21.0 million ¹⁶, an $160.5 million decrease from $181.432 million in 2024 ¹⁷, resulting from fair value assessments based on the decline in the company's stock price. Long-lived assets impairment increased by $9.1 million to $9.1 million ¹⁸ in 2025, due to the wind-down activities of the Roseville, Minnesota facility. Royalty liability interest expense – related parties increased by $1.3 million or 4% to $35.5 million ¹⁹ in 2025 from $34.190 million in 2024 ²⁰. Other interest income, net, decreased by $0.2 million or 31% to $0.4 million ²¹ in 2025 from $0.631 million in 2024 ²², driven by lower cash balances. Non-operating income, net, decreased by $8.9 million or 96% to $0.4 million ²³ in 2025 from $9.271 million in 2024 ²⁴, primarily due to fair value adjustments of Common Warrants.

Net cash used in operating activities was $50.6 million ²⁵ in 2025, a decrease of $7.5 million or 13% from $58.043 million in 2024 ²⁶, attributed to a $5.5 million decrease in net loss from cost reduction initiatives and a $1.9 million increase from changes in operating assets and liabilities. Net cash used in investing activities was $0.6 million ²⁷ in 2025, a decrease of $0.2 million or 28% from $0.808 million in 2024 ²⁸. Net cash provided by financing activities increased by $6.1 million or 15% to $46.6 million ²⁹ in 2025 from $40.598 million in 2024 ³⁰, primarily due to increased net proceeds from capital raised. As of December 31, 2025, Cibus had cash and cash equivalents of $9.9 million ³¹ and current liabilities of $16.9 million ³². The company's accumulated deficit stood at $858.3 million ³³ as of December 31, 2025.

During 2025, Cibus undertook significant operational developments to streamline its business focus and preserve capital. In June 2025, the company announced further streamlining efforts to concentrate working capital on the commercial advancement of Rice weed management traits ³⁴. This included a reduction in workforce of approximately 34 full-time employees, completed by December 31, 2025 ³⁵. In the fourth quarter of 2025, Cibus began winding down operations at its Roseville, Minnesota facility and is working to sublease it ³⁶. The company is consolidating its core operations to San Diego, California ³⁷. In January 2025, Cibus completed a registered direct offering, issuing 4,340,000 shares of Class A Common Stock and 4,700,000 pre-funded warrants, raising net proceeds of approximately $21.4 million ³⁸. In June 2025, another SEC-registered public offering of 15,714,285 shares of Class A Common Stock generated net proceeds of approximately $25.0 million ³⁹.

Cibus anticipates continued significant expenses and operating losses for the next several years as it advances its pipeline of productivity traits and expands commercial activities ⁴⁰. The company's ability to continue as a going concern depends on obtaining additional financing in the near term ⁴¹. Management expects to reduce its annual net cash usage to approximately $30.0 million or less during 2026, through cost reduction measures including streamlining staff and closing non-core facilities ⁴².

The primary growth area for Cibus is its Rice herbicide tolerance (HT) traits, HT1 and HT3, which are progressing toward targeted initial launches in Latin America beginning in 2027, with expansion into the United States in 2028 ⁴³. These traits are estimated to generate over $200.0 million in potential annual addressable royalties upon full commercialization across initial target markets ⁴⁴. The company has seven Rice partners in the United States and Latin America, representing approximately 5 million to 7 million estimated Cibus peak addressable acres ⁴⁵. Cibus is also initiating efforts to enter Asian markets (excluding China), starting with India, targeting commercial launches closer to 2030, with an estimated 120 million acres under cultivation in India and potential annual addressable royalties of $240 million ⁴⁶.

A secondary growth area is the sustainable ingredients program, including lauric oils and biofragrance products, which is partially partner-funded ⁴⁷. In the third quarter of 2025, Cibus achieved critical milestones with successful pre-commercial pilot runs for two biofragrance products, supporting expansion to commercial scale ⁴⁸. The global fragrance market is estimated to be valued at over $65.0 billion, representing a significant long-term opportunity for bio-based fragrance products ⁴⁹. A collaboration with Procter & Gamble (P&G) is ongoing to develop sustainable low carbon ingredients, with P&G partially funding a multi-year program ⁵⁰.

Operationally, Cibus is focused on consolidating its core operations to San Diego, California, while prioritizing resources toward advancing its Rice programs and completing ongoing non-Rice activities that are not partner-funded ⁵¹. Non-partner-funded activities outside of Rice, such as field testing, are being deferred ⁵². The company's R&D expenses are expected to decrease for the immediate future due to its streamlined business focus ⁵³. The large-scale field testing and seed increases for trait validation in the near term will primarily be centered around Rice ⁵⁴.

Regarding capital allocation, Cibus plans to finance future cash needs through existing cash, commercialization activities (including upfront and milestone payments, annual license fees, and royalties), government or third-party funding, and public or private equity or debt financings ⁵⁵. The company recently completed a January 2026 SEC-registered public offering, issuing 14,836,664 shares of Class A Common Stock, which generated net proceeds of approximately $19.8 million ⁵⁶. This, combined with cost-saving initiatives, is expected to fund planned operating expenses and capital expenditure requirements into late in the third quarter of 2026 ⁵⁷.

Management explicitly flagged several structural headwinds and execution risks. The company has incurred significant losses and anticipates continued losses for several years, with substantial doubt about its ability to continue as a going concern without additional near-term financing ⁵⁸. The streamlined business focus, while preserving capital, may lead to operational and strategic challenges, including potential loss of institutional knowledge, unplanned attrition, and reduced employee morale ⁵⁹. There is no assurance that cost reduction measures will achieve stated cash burn targets or result in improved cash flow and financial stability ⁶⁰. The success of licensing intellectual property and commercialization depends on third-party seed companies, over whom Cibus has limited direct control ⁶¹. Estimates and forecasts for market demand, accessible acres, and trait fees are inherently uncertain and may prove inaccurate, particularly regarding the evolving EU regulatory landscape for gene-edited products ⁶².

Geographic, regulatory, and macro factors also pose constraints. While regulatory frameworks in the United States, Canada, and certain Latin American countries are favorable for gene-edited products, and positive developments are occurring in the EU (excluding HT traits), there is no guarantee that these regulations will not change adversely ⁶³. Specifically, access to European planted acres for Cibus's weed management (HT) traits is expected to be constrained under the new EU framework ⁶⁴. The regulatory environment varies greatly by region, and lack of international harmonization, coupled with vocal opponents of gene editing, could negatively impact commercialization efforts ⁶⁵. The agricultural industry is susceptible to volatile commodity and raw material prices, adverse weather conditions, and geopolitical conflicts, all of which could affect demand for Cibus's traits and its licensees' sales ⁶⁶.

Cibus faces material risks including its ongoing significant losses and substantial doubt about its ability to continue as a going concern without additional near-term financing ⁶⁷. The company operates in a highly competitive market with competitors possessing substantially greater financial and technical resources ⁶⁸. Its streamlined business focus, while intended to preserve capital, may lead to operational and strategic challenges such as loss of institutional knowledge, unplanned attrition, and reduced employee morale ⁶⁹. The success of Cibus's business model, which relies on licensing intellectual property to third parties, is dependent on the efforts and success of these licensees, over whom Cibus has limited control ⁷⁰. Estimates and forecasts regarding market demand, accessible acres, and trait fees are inherently uncertain and may prove inaccurate, particularly concerning the evolving regulatory landscape for gene-edited products ⁷¹. Regulatory changes in key jurisdictions could subject Cibus's products to more burdensome standards, increasing costs and delaying commercialization; specifically, access to European planted acres for Cibus's weed management (HT) traits is expected to be constrained under the new EU framework ⁷². The agricultural industry is susceptible to volatile commodity and raw material prices, adverse weather conditions, and geopolitical conflicts, which could negatively impact demand and royalty revenues ⁷³. The company's intellectual property protection is crucial, and challenges to patents, or failure to adequately protect trade secrets, could impair its competitive position ⁷⁴. Cibus is a holding company dependent on distributions from its subsidiary, Cibus Global, to cover expenses ⁷⁵. The Royalty Liability, which requires payments to certain related parties, including directors and officers, equal to 10 percent of specified Subject Revenues once aggregate Subject Revenues cash inflow exceeds $50.0 million in any consecutive 12-month period, could adversely affect cash flow and create conflicts of interest ⁷⁶. As of December 31, 2025, the aggregated, but unpaid, Royalty Payments amounted to $0.6 million ⁷⁷.

Management's message to shareholders emphasizes the advancement of the company's strategy and the transformative potential of its RTDS technology platform, positioning Cibus at an important inflection point in the agricultural industry, particularly with regulatory progress globally and its Rice traits moving into customer germplasm ⁷⁸. The company has incurred net losses since inception, with a net loss of $132.2 million ⁷⁹ for the year ended December 31, 2025, and an accumulated deficit of $858.3 million ⁸⁰. Management explicitly states that there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the issuance date of the financial statements without obtaining additional financing in the near term ⁸¹. The company expects to continue to incur significant expenses and operating losses for the next several years ⁸². Strategic priorities include concentrating working capital expenditures on the commercial advancement of the company's weed management traits for Rice and completing ongoing non-Rice activities that are partner-funded, while deferring non-partner-funded activities outside of Rice, such as field testing ⁸³. Management anticipates reducing its annual net cash usage to approximately $30.0 million or less ⁸⁴ during 2026 through cost reduction measures, including streamlining staff and closing certain non-core facilities, expecting these efforts to contribute toward improved cash flow and financial stability ⁸⁵.